Wall Street brokerages forecast that Myriad Genetics, Inc. (NASDAQ:MYGN) will post earnings of $0.21 per share for the current quarter, Zacks reports. Five analysts have made estimates for Myriad Genetics’ earnings. The lowest EPS estimate is $0.19 and the highest is $0.28. Myriad Genetics reported earnings of $0.23 per share in the same quarter last year, which indicates a negative year over year growth rate of 8.7%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, November 7th.
According to Zacks, analysts expect that Myriad Genetics will report full-year earnings of $1.01 per share for the current financial year, with EPS estimates ranging from $0.91 to $1.06. For the next year, analysts forecast that the firm will report earnings of $1.16 per share, with EPS estimates ranging from $0.93 to $1.41. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Myriad Genetics.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The business had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. During the same quarter last year, the business earned $0.36 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis.
MYGN has been the subject of a number of research analyst reports. BidaskClub raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Monday, July 17th. Barclays PLC dropped their target price on shares of Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $23.00 target price (up from $21.00) on shares of Myriad Genetics in a research note on Thursday, August 10th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $22.00 target price on shares of Myriad Genetics in a research note on Friday, July 14th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. Myriad Genetics presently has an average rating of “Hold” and an average price target of $21.22.
Several large investors have recently bought and sold shares of MYGN. Archford Capital Strategies LLC increased its stake in Myriad Genetics by 87,146.7% in the second quarter. Archford Capital Strategies LLC now owns 13,087 shares of the company’s stock worth $713,000 after buying an additional 13,072 shares during the period. Public Employees Retirement System of Ohio increased its stake in Myriad Genetics by 1.0% in the second quarter. Public Employees Retirement System of Ohio now owns 143,036 shares of the company’s stock worth $3,696,000 after buying an additional 1,480 shares during the period. Piedmont Investment Advisors LLC increased its stake in Myriad Genetics by 53.9% in the second quarter. Piedmont Investment Advisors LLC now owns 130,025 shares of the company’s stock worth $3,360,000 after buying an additional 45,512 shares during the period. CS Mckee LP increased its stake in Myriad Genetics by 0.3% in the second quarter. CS Mckee LP now owns 30,000 shares of the company’s stock worth $775,000 after buying an additional 100 shares during the period. Finally, Moors & Cabot Inc. increased its stake in Myriad Genetics by 33.4% in the second quarter. Moors & Cabot Inc. now owns 21,475 shares of the company’s stock worth $557,000 after buying an additional 5,375 shares during the period.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/09/17/0-21-earnings-per-share-expected-for-myriad-genetics-inc-mygn-this-quarter.html.
Myriad Genetics (NASDAQ MYGN) traded down 0.79% on Wednesday, hitting $30.25. 1,164,000 shares of the company were exchanged. Myriad Genetics has a one year low of $15.15 and a one year high of $30.73. The stock has a 50 day moving average price of $26.62 and a 200 day moving average price of $22.33. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 94.83 and a beta of 0.25.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.